RCS - GenIP PLC - Healthcare Technology Event in Singapore

GenipAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3193Ma&default-theme=true

RNS Number : 3193M  GenIP PLC  15 November 2024

 

 

 

 

15 November 2024

GenIP Plc

("GenIP" or the "Company")

GenIP congratulates NHIC on its 10th Anniversary Milestone

GenIP is pleased to be a corporate sponsor of the National Health Innovation
Centre Singapore's (NHIC) 10th Anniversary Appreciation dinner, which took
place on 14th November 2024. The gathering brought together healthcare
professionals, industry leaders, and stakeholders from across the region to
recognise a decade of clinical innovations that have positively impacted the
healthcare sector.

Supporting the Future of Healthcare Innovation

GenIP is delighted to join other key players in championing healthcare
innovation. Our GenAI-enhanced services aim to accelerate the
commercialisation of promising technologies that can improve quality of life.
The appreciation dinner was a unique opportunity for GenIP to connect with
innovators who share the same commitment in contributing to Singapore's
vibrant healthcare landscape.

Ms Melissa Cruz, CEO of GenIP, commented:

"We're honoured to be part of this milestone event and look forward to
collaborating with other visionaries to drive innovation in the implementation
and commercialisation of healthcare technology."

Dr Pauline Tay, Director of NHIC, commented:

"We are heartened to have the support of companies, including GenIP. As we
cross this milestone, we look forward to continuing to work with our ecosystem
partners and industry colleagues to forge new innovations in healthcare
delivery."

 

 

 

For further information regarding GenIP, please visit www.genip.ai, or
contact:

GenIP Plc

Melissa Cruz,
CEO
Tel: +44 (0) 20 3368 3090

Redchurch Communications (Financial PR)

John
Casey
genip@weareredchurch.com

 

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulations would be disseminated as an RNS
regulatory announcement and not on Reach.

 

Notes to Editors

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to
help companies, research institutions and venture funds assess and
commercialise new discoveries. GenIP combines expert human technical review
with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1.   Invention Evaluator: Provides bespoke research reports that assess the
market potential of new technological innovations and discoveries using
AI-driven proprietary software; and

 

2.   Vortechs: which is an executive recruitment platform that through
advanced machine learning algorithms and natural language processing
technologies assists in matching technology organisations with experienced
executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help
organisations to evaluate and commercialise their technological innovations.

 

Company Strategy

GenIP's goal is to create a leading Generative AI analytic services company.
To achieve this, the Company has established three strategic pillars:

 

●    Organically grow InventionEvaluator and Vortechs' revenue through
institutional and corporate connections as well as increase client pipeline
through marketing, advertising and social media spend.

●    Expand the Generative AI service offerings within InventionEvaluator
and Vortechs' to reach new customers and improve margins.

●    Bolt-on acquisitions of additional Generative AI services that are
helpful to our clients and have demonstrated initial market traction.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

 

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABIBATMTIBBPI